Research programme: thyroid cancer therapeutics - MGI Pharma

Drug Profile

Research programme: thyroid cancer therapeutics - MGI Pharma

Alternative Names: AKR-201; Tetrac; Tetraiodothyroacetic acid

Latest Information Update: 23 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beartownpharma
  • Developer AkaRx
  • Class
  • Mechanism of Action Thyrotropin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer

Highest Development Phases

  • No development reported Thyroid cancer

Most Recent Events

  • 06 Jan 2010 AkaRx has been acquired by Eisai Inc
  • 29 Jan 2008 MGI Pharma has been acquired by Eisai
  • 12 Oct 2007 AKR 201 licensed to MGI Pharma worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top